Disability-relevant demyelination in multiple sclerosis: five-year evolution following diagnosis

Improved understanding of how myelin damage contributes to disability in multiple sclerosis (MS) is needed to inform targeted therapeutic strategies and improve clinical trial platforms. Magnetization transfer saturation (MTsat) and T1 relaxometry provide in vivo quantitative MRI measures of myelin integrity, and may offer insights into disability-relevant pathology beyond inflammatory relapse. This longitudinal study explores the relationship between early demyelination and disability progression over the first five years following diagnosis. 62 people with relapsing-remitting (pwRR)MS ([≤

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.